期刊文献+

诱骗受体3在上皮性卵巢癌组织中的表达与临床病理特征的相关性研究 被引量:4

Association between expression of decoy receptor 3 in patients with epithelial ovarian cancer and clinical pathology characteristics
原文传递
导出
摘要 目的研究诱骗受体3(DcR3)在人上皮性卵巢癌组织的表达及其临床意义。方法对2012年3月至2015年6月我院妇产科收治并手术治疗的66例上皮性卵巢癌组织及41例良性卵巢肿瘤组织的临床资料及组织病理学标本进行回顾性分析。用免疫组织化学SP法检测良性卵巢肿瘤组织及上皮性卵巢癌组织中DcR3蛋白的表达水平,用已知阳性组织切片作为阳性对照,以PBS溶液代替一抗作为阴性对照,分析其表达与患者临床病理学特征及生存时间的关系。结果在上皮性卵巢癌中,Ⅰ~Ⅱ与Ⅲ~Ⅳ期的DcR3阳性表达率分别为68.4%和89.4%,Ⅲ~Ⅳ期与Ⅰ~Ⅱ期比较差异有统计学意义(P〈0.05);高、低2个分化组DcR3阳性表达率分别为66.7%和91.1%,低分化组与高分化组比较差异有统计学意义(P〈0.05);淋巴结转移组的DcR3阳性表达率为91.3%,与无转移组的65.0%比较差异有统计学意义(P〈0.05)。免疫组化染色显示,DcR3主要在细胞质和细胞膜中表达,DcR3在上皮性卵巢癌组织及良性卵巢肿瘤组织中的阳性表达率分别为83.3%,29.3%,癌组织与良性肿瘤组织比较差异有统计学意义(P〈0.05)。DcR3阳性患者的中位生存时间为28.4个月,与阴性患者的50.2个月比较差异有统计学意义(HR=1.90,95%CI:1.09~3.66,P〈0.05)。结论 DcR3蛋白可作为卵巢癌患者的预后不良的生物学标志物。 Objective To evaluate the association between decoy receptor3( DcR3) expression and clinical pathology characteristics in patients with epithelial ovarian cancer. Methods Sixty- six patiens with epithelial ovarian cancer and 41 cases with benign ovarian tumor were retrospectively analyzed from Mar 2012 to Jun 2015 in our hospital. The cancer tissue and benign ovarian tumor tissue were tested for decoy receptor 3( DcR3) expression by immunohistochemical method. The known positive sample was used as positive control and the PBS solution was used as negative blank control. The clinical pathology characteristic prognosis with DcR3 expression was evaluated by statistical software. The overall survival was also assessed according to DcR3 positive or negative.Results The clinical pathology analysis showed that the DcR3 positive expression rate were 68. 4% and 89. 4% for Ⅰ- Ⅱ and Ⅲ- Ⅳ stage patients with statistical difference( P 〈 0. 05). DcR3 positive expressionrate were 66. 7% and 91. 1% for well differentiation and poor differentiation group respectively with statistical difference( P 〈 0. 05). The DcR3 positive expression rate in lymph node metastasis group was much higher than that of non- metastasis group( 91. 3% vs 65. 0%) with statistical difference( P 〈 0. 05). DcR3 was mainly expressed in cytoplasm and cell membrane. The DcR3 positive expression in cancer tissue and benign tumor tissue were 83. 3% and29. 3% respectively which indicated cancer tissue significant higher than that of benign tumor tissue( P 〈 0. 05). The median survival for DcR3 positive and negative patients were 28. 4 months and 50. 2 months( HR = 1. 90,95% CI:1. 09- 3. 66,P 〈 0. 05). Conclusion DcR3 was highly expressed in cancer tissue and associated with poor prognosis,which could be biomarker for prognosis.
作者 林瑶 黄小莉
出处 《中国临床药理学杂志》 CAS CSCD 北大核心 2016年第18期1670-1672,1676,共4页 The Chinese Journal of Clinical Pharmacology
基金 福建省教育厅基金资助项目(JA131595)
关键词 上皮性卵巢癌 诱骗受体 临床特征 预后 epithelial ovarian cancer decoy receptor clinical characteristics prognosis
  • 相关文献

参考文献9

  • 1SIEGEL R, MA J, ZOU Z, et al. Cancer statistics, 2014[J]. CA Cancer J Clin, 2014,64( 1 ) :9 -29.
  • 2SIEGEL R, NAISHADHAM D, JEMAL A. Cancer statistics, 2013 ~J]. CA Cancer J Clin, 2013,63(1) :11 -30.
  • 3HUNN J, RODRIGUEZ G C. Ovarian cancer: etiology, risk factors, and epidemiology[ J]. Clin Obstet Gynccol, 2012,55(1) :3 -23.
  • 4CRAMER D W. The epidemiology of endometrial and ovarian cancer [J]. Hematol Oncol Clin North Am, 20t2,26( 1 ) :1 - 12.
  • 5CONNOR J P, FELDER M. Ascites from epithelial ovarian cancer contain high levels of functional decoy receptor 3 ( DcR3 ) and is associated with platinum resistance [ J ]. Gynecol Oncol, 2008,111 (2) :330-335.
  • 6XIONG G, GUO H, GE X, et al. Decoy receptor 3 expression in esophageal squamous cell carcinoma: correlation with turnout invasion and metastasis[J]. Biomarkers, 2011,16(2) :155 - 160.
  • 7程丽,杨玉环,周翠荣,姚晶萍,牛娜,刘乾.诱骗受体3在上皮性卵巢癌组织中的表达及临床意义[J].现代肿瘤医学,2015,23(1):116-119. 被引量:6
  • 8CHANG W C, CHEN J Y, LEE C H, et al. Expression of decoy re- ceptor 3 in diffuse sclerasing variant of papillary thyroid carcinoma: correlation with M2 macrophage differentiation and lymphatic invasion [J]. Thyroid, 2013,23(6) :720 -726.
  • 9LIN W W, HSIEH S L. Decoy receptor 3 : a pleiotropic immuno- mo dulator and biomarker for inflammatory diseases, autoimmune diseases and cancer [ J ]. Bioehem Pharmacol, 2011 , 81 ( 7 ) : 838-847.

二级参考文献16

  • 1沈宏伟,吴育连,彭淑牖.DcR3基因表达与肝癌细胞的凋亡及其相互关系[J].中华外科杂志,2004,42(22):1396-1397. 被引量:2
  • 2钟智强,兰小鹏,杨湘越,李卫滨,张鲁榕,朱忠勇.DcR3基因在原发性肺癌的扩增和表达及临床意义[J].福州总医院学报,2007,14(3):166-168. 被引量:2
  • 3Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009 [ J ]. CA Cancer J Clin ,2009,59 (4) :225 - 249.
  • 4Larsen IK, SmKstuen M, Johannesen TB, et al. Data quality at the Cancer Registry of Norway : an overview of comparability, complete- ness,validity and timeliness[ J]. Eur J Cancer,2009,45 ( 7 ) : 1218 - 1231.
  • 5Pitti RM, Masters SA, Lawrence DA, et al. Genomieamp lification of a decoy receptor for fas ligand in lung and colon cancer [ J ]. Na- ture,1998,396(6712) :699 -703.
  • 6Gill RM, Hunt JS. Soluble receptor( DeR3 ) and cellular inhibitor of apoptosis - 2 ( el "AP - 2 ) protect human Cytotrophoblast cells a- gainst LIGHTmediated apoptosis[ J]. Am J Patho1,2004,165 ( 1 ) : 309 -317.
  • 7Bai C, Connolly B, Metzker ML, et al. Overexpression of M68/DcR3 in human gastrointestinal tract tumors independent of gene amplifi- cation and its location in a four- gene cluster[ J]. Proc Natl Acad Sei USA ,2000,97(3 ) : 1230 - 1235.
  • 8Ren Z,Zhu J,Gu H,et al. Decoy receptor 3 polymorphisms are not associated with the risk of esophageal cancer in a Chinese popula- tion[J]. Biomarkers,2014,5:2.
  • 9Yu W,Xu YC,Tao Y,et al. DcR3 regulates the growth and meta- static potential of SW480 colon cancer cells[ J]. Oneol Rep,2013, 30(6) :2741 -2748.
  • 10Huang S, Chen G, Dang Y, et al. Overexpression of DcR3 and its significance on tumor cell differentiation and proliferation in glioma [J]. Sci World J,2014,60:236.

共引文献5

同被引文献31

引证文献4

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部